Literature DB >> 9486103

Anti-alpha 4 integrin antibody induces apoptosis in murine thymocytes and staphylococcal enterotoxin B-activated lymph node T cells.

E Z Tchilian1, J J Owen, E J Jenkinson.   

Abstract

We have shown that an antibody (9C10) to the alpha 4 integrin induces apoptosis in murine immature CD4+ CD8+ thymocytes and in activated (but not resting) mature lymph node T cells. In both cases, apoptosis is blocked by the highly selective protein kinase C (PKC) inhibitor Ro31.8425, suggesting that 9C10 induces signalling through the alpha 4 integrin resulting in PKC activation leading to apoptosis. Overall, our results indicate the potential role of the alpha 4 integrin-mediated interactions in apoptosis induction during T-cell development and following mature T-cell activation.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9486103      PMCID： PMC1363791          DOI： 10.1046/j.1365-2567.1997.00351.x

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


  38 in total

1.  Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures.

Authors:  C A Smith; G T Williams; R Kingston; E J Jenkinson; J J Owen
Journal:  Nature       Date:  1989-01-12       Impact factor: 49.962

2.  Antigen-independent T cell activation mediated by a very late activation antigen-like extracellular matrix receptor.

Authors:  K Takahashi; T Nakamura; H Adachi; H Yagita; K Okumura
Journal:  Eur J Immunol       Date:  1991-06       Impact factor: 5.532

Review 3.  Positive and negative selection of the alpha beta T-cell repertoire in vivo.

Authors:  H von Boehmer
Journal:  Curr Opin Immunol       Date:  1991-04       Impact factor: 7.486

4.  Receptor-stimulated death pathway is opened by antigen in mature T cells.

Authors:  J H Russell; C L White; D Y Loh; P Meleedy-Rey
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

5.  VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site.

Authors:  M J Elices; L Osborn; Y Takada; C Crouse; S Luhowskyj; M E Hemler; R R Lobb
Journal:  Cell       Date:  1990-02-23       Impact factor: 41.582

6.  T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1.

Authors:  M L Dustin; T A Springer
Journal:  Nature       Date:  1989-10-19       Impact factor: 49.962

7.  Regulated expression and binding of three VLA (beta 1) integrin receptors on T cells.

Authors:  Y Shimizu; G A Van Seventer; K J Horgan; S Shaw
Journal:  Nature       Date:  1990-05-17       Impact factor: 49.962

8.  Costimulation with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 augments activation-induced death of antigen-specific CD4+ T lymphocytes.

Authors:  N K Damle; K Klussman; G Leytze; A Aruffo; P S Linsley; J A Ledbetter
Journal:  J Immunol       Date:  1993-09-01       Impact factor: 5.422

9.  A monoclonal antibody to VLA-4 alpha-chain (CDw49d) induces homotypic lymphocyte aggregation.

Authors:  J L Bednarczyk; B W McIntyre
Journal:  J Immunol       Date:  1990-02-01       Impact factor: 5.422

10.  A monoclonal antibody (NKI-L16) directed against a unique epitope on the alpha-chain of human leukocyte function-associated antigen 1 induces homotypic cell-cell interactions.

Authors:  G D Keizer; W Visser; M Vliem; C G Figdor
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422
View more
  7 in total

1.  RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 α5β1 integrin co-signaling.

Authors:  Zhuo Wang; Russell J Collighan; Stephane R Gross; Erik H J Danen; Gertraud Orend; Dilek Telci; Martin Griffin
Journal:  J Biol Chem       Date:  2010-10-07       Impact factor: 5.157

Review 2.  Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.

Authors:  Henrik Gensicke; David Leppert; Özgür Yaldizli; Raija L P Lindberg; Matthias Mehling; Ludwig Kappos; Jens Kuhle
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

3.  Fab'-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis.

Authors:  Hamed Laroui; Emilie Viennois; Bo Xiao; Brandon S B Canup; Duke Geem; Timothy L Denning; Didier Merlin
Journal:  J Control Release       Date:  2014-05-05       Impact factor: 9.776

4.  Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.

Authors:  Ludwig Kappos; Paul W O'Connor; Christopher H Polman; Patrick Vermersch; Heinz Wiendl; Amy Pace; Annie Zhang; Christophe Hotermans
Journal:  J Neurol       Date:  2013-01-05       Impact factor: 4.849

5.  Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders.

Authors:  Aiden Haghikia; Moritz Perrech; Bartosz Pula; Sabrina Ruhrmann; Anja Potthoff; Norbert H Brockmeyer; Susan Goelz; Heinz Wiendl; Hans Lindå; Tjalf Ziemssen; Sergio E Baranzini; Tor-Björn Käll; Dietmar Bengel; Tomas Olsson; Ralf Gold; Andrew Chan
Journal:  PLoS One       Date:  2011-04-20       Impact factor: 3.240

6.  alpha(4)-integrin mediates neutrophil-induced free radical injury to cardiac myocytes.

Authors:  B Y Poon; C A Ward; C B Cooper; W R Giles; A R Burns; P Kubes
Journal:  J Cell Biol       Date:  2001-03-05       Impact factor: 10.539

7.  CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS.

Authors:  Volker Limmroth; Frederik Barkhof; Nuket Desem; Mark P Diamond; George Tachas
Journal:  Neurology       Date:  2014-09-19       Impact factor: 9.910
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.